Mr. Stephen Van Deventer reports

PREVECEUTICAL ANNOUNCES UPDATE TO NON-BROKERED PRIVATE PLACEMENT

Preveceutical Medical Inc. has arranged a non-brokered private placement of up to 16,666,667 units in the capital of the company at a price of three cents per unit for gross proceeds of up to $500,000. Each unit consists of one common share of the company and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of five cents per warrant share for a period of 24 months from the closing of the offering; provided that the expiry of the warrants can be accelerated if the closing price of the company's common shares on the Canadian Securities Exchange (the CSE) is eight cents or greater for a minimum of 10 consecutive trading days, and a notice of acceleration is provided in accordance with the terms of the warrants. News issued on March 10, 2025, for the private placement has been increased to $500,000.

Finders' fees may be paid. The company intends to use the aggregate gross proceeds from the sale of the offering to pay outstanding payables, for operating expenses and for general working capital purposes.

All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the closing. Completion of the offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the CSE.

About Preveceutical Medical Inc.

Preveceutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. Preveceutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

We seek Safe Harbor.